Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
6 evidence topics · 5 sources
Absorption, dose proportionality, accumulation, and steady state in healthy participants
“ESK‐001 was rapidly absorbed with systemic exposures generally increasing dose‐proportionally across all cohorts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean terminal half‐life ranged from 8 to 13 h with no to minimal accumulation of ESK‐001 following q.d. doses and ~2‐fold accumulation following Q12 doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following both single (≤100 mg) and multiple (≤60 mg q.d. and ≤40 mg Q12) dose administration, ESK‐001 was rapidly absorbed into the systemic circulation and afterward eliminated in an approximately monoexponential manner with less than 1% renal excretion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The systemic exposure of ESK‐001 showed linear dose‐dependent PK characteristics across the dose range, with steady state achieved by 3–5 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physicochemical properties, permeability, and tissue distribution
“ESK‐001 was designed to deliver best‐in‐class pharmacokinetics (PK), including rapid absorption, low PK variability, high permeability with no efflux, and good penetration into relevant tissues.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Molecular weight <500 g/mol.” (opens the source at this quote in a new tab)
“Low polar surface area.” (opens the source at this quote in a new tab)
Elimination half-life as stated by the manufacturer and a narrative review
“Envudeucitinib demonstrated a favorable pharmacokinetic profile characterized by rapid absorption, an elimination half-life of approximately 8 h, a dose-proportional increase in exposure, minimal renal clearance, and low interindividual variability” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic clearance, metabolites, and deuteration
“Envudeucitinib is primarily cleared through hepatic metabolism” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies evaluating absorption, distribution, metabolism, and excretion of envudeucitinib in healthy volunteers identified one major and seven minor metabolites (data on file).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The major metabolite is pharmacologically inactive with no significant off-target effects; minor metabolites contribute minimally to the overall pharmacologic activity of envudeucitinib (data on file).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Envudeucitinib includes a deuterated methyl triazole moiety that may enhance its metabolic stability by reducing cytochrome P450 1A2 (CYP1A2)-mediated demethylation, mitigating potential metabolite-driven off-target effects, and maximizing the pharmacodynamic response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote